BridgeMD
New treatment option for mCRPC (Metastatic Castration-resistant Prostate Cancer)
Official title Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity
ClinicalTrials.gov ID: NCT07302763
What this study is testing
- What it's testing
- Imaging modalities currently used in the clinics do not image cancer, but the effect ofncancer on bone (bone scan) or on the anatomy (CT-scan). Bone scan and CT-scan are therefore named conventional imaging (CI) modalities.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Assign male at birth, any gender ≥ 18 years old;
- Histologically or cytologically proven adenocarcinoma of the prostate;
- Metastatic disease documented by at least 3 metastatic active lesions\ , \ \ on whole body bone scan and/or measurable soft tissue on CT-scan (lymph...
- CRPC \& post-androgen receptor pathway inhibitor (ARPI) defined by progression under continuous castration (measured serum testosterone ≤50 ng/dL...
- Eligible for taxane chemotherapy or PSMA-radioligand therapy (before imaging); 6-Able and willing to provide signed informed consent and to comply...
You likely can't join if
- 1\. Another non-cutaneous malignancy or melanoma diagnosed in the past 5 years; 2. Currently under a assigned by chance controlled trial with unknown...
See the full eligibility criteria
- Assign male at birth, any gender ≥ 18 years old;
- Histologically or cytologically proven adenocarcinoma of the prostate;
- Metastatic disease documented by at least 3 metastatic active lesions\ , \ \ on whole body bone scan and/or measurable soft tissue on CT-scan (lymph nodes and visceral lesions);
- CRPC \& post-androgen receptor pathway inhibitor (ARPI) defined by progression under continuous castration (measured serum testosterone ≤50 ng/dL [1.73 nM]) AND an ARPI (darolutamide, apalutamide, enzalutamide or...
- Eligible for taxane chemotherapy or PSMA-radioligand therapy (before imaging); 6-Able and willing to provide signed informed consent and to comply with protocol requirements.
- Metastatic lesions on imaging are defined either: ≥ 10 mm on CT scan or caliper (for lymph nodes, see below), ≥ 20 mm on chest X-ray, lymph node ≥ 10 mm or having grown by ≥ 5 mm from baseline CT, any metastasis...
- The reference imaging (scan with 3 metastases) confirming eligibility must be done either: 1) after biochemical progression on treatment OR 2) ≥ 90 days after last treatment has begun if imaging was performed while...
- 1\. Another non-cutaneous malignancy or melanoma diagnosed in the past 5 years; 2. Currently under a assigned by chance controlled trial with unknown allocation; 3-Any disease or condition limiting the patient's...
The study team makes the final eligibility decision.
Where it's taking place
- Québec, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Québec, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.